IDEAS: Improving Design, Evaluation and Analysis of early drug development Studies

Project: Research

Description

Improving Design, Evaluation and Analysis of early drug development Studies (IDEAS) - Marie Curie Innovative Training Network

Acronym	H2020: IDEAS - MC
Status	Finished
Effective start/end date	1/01/15 → 31/12/18
Links	http://www.ideas-itn.eu

Jaki, Thomas (Principal Investigator)

Research outputs

Quantifying the association between progression-free survival and overall survival in oncology trials using Kendall's tau.
Research output: Contribution to journal › Journal article › peer-review
Generalization of Cramér-Rao and Bhattacharyya inequalities for the weighted covariance matrix
Research output: Contribution to journal › Journal article › peer-review
A review of the deterministic and diffusion approximations for stochastic chemical reaction networks
Research output: Contribution to journal › Journal article › peer-review
A Bayesian model to estimate the cutoff and the clinical utility of a biomarker assay
Research output: Contribution to journal › Journal article › peer-review
A proposal for a new PhD level curriculum on quantitative methods for drug development
Research output: Contribution to journal › Journal article › peer-review
An information-theoretic Phase I/II design for molecularly targeted agents that does not require an assumption of monotonicity
Research output: Contribution to journal › Journal article › peer-review
A novel measure of drug benefit–risk assessment based on Scale Loss Score
Research output: Contribution to journal › Journal article › peer-review
Adaptive designs for complex dose finding studies
Research output: Thesis › Doctoral Thesis
A benchmark for dose finding studies with continuous outcomes
Research output: Contribution to journal › Journal article › peer-review
Randomized dose-escalation designs for drug combination cancer trials with immunotherapy
Research output: Contribution to journal › Journal article › peer-review
Subgroup identification in clinical trials via the predicted individual treatment effect
Research output: Contribution to journal › Journal article › peer-review
A robust Bayesian meta-analytic approach to incorporate animal data into phase I oncology trials
Research output: Contribution to journal › Journal article › peer-review
Loss Functions in Restricted Parameter Spaces and Their Bayesian Applications
Research output: Contribution to journal › Journal article › peer-review
Model selection based on combined penalties for biomarker identification
Research output: Contribution to journal › Journal article › peer-review
Response to comments on Jaki et al., A proposal for a new PhD level curriculum on quantitative methods for drug development. Pharm Stat 17(5):593-606, Sep/Oct 2018., DOI https://doi.org/10.1002/pst.1873
Research output: Contribution to journal › Letter › peer-review
An information-theoretic approach for selecting arms in clinical trials
Research output: Contribution to journal › Journal article › peer-review
Bayesian sequential integration within a preclinical pharmacokinetic and pharmacodynamic modeling framework: Lessons learned
Research output: Contribution to journal › Journal article › peer-review
A flexible design for advanced Phase I/II clinical trials with continuous efficacy endpoints
Research output: Contribution to journal › Journal article › peer-review
Improving safety of the continual reassessment method via a modified allocation rule
Research output: Contribution to journal › Journal article › peer-review
A Bayesian decision-theoretic approach to incorporate preclinical information into phase I oncology trials
Research output: Contribution to journal › Journal article › peer-review
A surface-free design for phase I dual-agent combination trials
Research output: Contribution to journal › Journal article › peer-review
Using a Dose-Finding Benchmark to Quantify the Loss Incurred by Dichotomisation in Phase II Dose-Ranging Studies
Research output: Contribution to journal › Journal article › peer-review
Using a dose-finding benchmark to quantify the loss incurred by dichotomization in Phase II dose-ranging studies
Research output: Contribution to journal › Journal article › peer-review
A Benchmark for Dose Finding Studies with Unknown Ordering
Research output: Contribution to journal › Journal article › peer-review

Research

IDEAS: Improving Design, Evaluation and Analysis of early drug development Studies

Description

Links

Research outputs

Quantifying the association between progression-free survival and overall survival in oncology trials using Kendall's tau.

Generalization of Cramér-Rao and Bhattacharyya inequalities for the weighted covariance matrix

A review of the deterministic and diffusion approximations for stochastic chemical reaction networks

A Bayesian model to estimate the cutoff and the clinical utility of a biomarker assay

A proposal for a new PhD level curriculum on quantitative methods for drug development

An information-theoretic Phase I/II design for molecularly targeted agents that does not require an assumption of monotonicity

A novel measure of drug benefit–risk assessment based on Scale Loss Score

Adaptive designs for complex dose finding studies

A benchmark for dose finding studies with continuous outcomes

Randomized dose-escalation designs for drug combination cancer trials with immunotherapy

Subgroup identification in clinical trials via the predicted individual treatment effect

A robust Bayesian meta-analytic approach to incorporate animal data into phase I oncology trials

Loss Functions in Restricted Parameter Spaces and Their Bayesian Applications

Model selection based on combined penalties for biomarker identification

Response to comments on Jaki et al., A proposal for a new PhD level curriculum on quantitative methods for drug development. Pharm Stat 17(5):593-606, Sep/Oct 2018., DOI https://doi.org/10.1002/pst.1873

An information-theoretic approach for selecting arms in clinical trials

Bayesian sequential integration within a preclinical pharmacokinetic and pharmacodynamic modeling framework: Lessons learned

A flexible design for advanced Phase I/II clinical trials with continuous efficacy endpoints

Improving safety of the continual reassessment method via a modified allocation rule

A Bayesian decision-theoretic approach to incorporate preclinical information into phase I oncology trials

A surface-free design for phase I dual-agent combination trials

Using a Dose-Finding Benchmark to Quantify the Loss Incurred by Dichotomisation in Phase II Dose-Ranging Studies

Using a dose-finding benchmark to quantify the loss incurred by dichotomization in Phase II dose-ranging studies

A Benchmark for Dose Finding Studies with Unknown Ordering

Quick Links

Connect With Us

Faculties & Depts

Contact Us